BASAGLAR

Peak

insulin glargine

BLASUBCUTANEOUSSOLUTION
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21

Mechanism of Action

insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and…

Pharmacologic Class:

Insulin Analog

Clinical Trials (5)

NCT07076199Phase 3Recruiting

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
NCT06340854Phase 3Completed

A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes

Started Apr 2024
429 enrolled
Diabetes, Type 2
NCT06269107Phase 3Completed

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

Started Feb 2024
485 enrolled
Type 2 Diabetes
NCT06109311Phase 3Completed

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Started Nov 2023
546 enrolled
Type 2 Diabetes
NCT05803421Phase 3Active Not Recruiting

A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Started Apr 2023
2,749 enrolled
Type 2 DiabetesObesityOverweight or Obesity+3 more